Sculati Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sculati Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Sell	3,146 -134	-4%	-$59.4K	0.51%	53
2026 Q1	$1.46M	Sell	3,280 -80	-2%	-$37.3K	0.54%	55
2025 Q4	$1.52M	Buy	3,360 +32	+1%	+$13.8K	0.54%	54
2025 Q3	$1.3M	Buy	3,328 +149	+5%	+$62.3K	0.46%	59
2025 Q2	$1.42M	Buy	3,179 +242	+8%	+$112K	0.53%	57
2025 Q1	$1.42M	Buy	2,937 +381	+15%	+$178K	0.58%	49
2024 Q4	$1.03M	Buy	2,556 +25	+1%	+$11.6K	0.41%	59
2024 Q3	$1.18M	Buy	2,531 +579	+30%	+$278K	0.47%	58
2024 Q2	$915K	Buy	1,952 +507	+35%	+$220K	0.39%	61
2024 Q1	$604K	Buy	+1,445	New	+$611K	0.26%	72

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sculati Wealth Management's VRTX Position: Q2 2026 in Review

Sculati Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q2 2026, selling an estimated $59.4K and leaving 3,146 shares worth $1.53M. The position accounts for 0.51% of the portfolio, ranked #53.

Sculati Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Sculati Wealth Management held 3,146 shares of Vertex Pharmaceuticals worth $1.53M as of Q2 2026.
Sculati Wealth Management sold 134 Vertex Pharmaceuticals shares in Q2 2026, an estimated $59.4K.
Vertex Pharmaceuticals made up 0.51% of Sculati Wealth Management's portfolio in Q2 2026, its #53 holding.
Sculati Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sculati Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.